Immunomedics inks deal with Syncor
Philips signs off on CEO’s replacementImmunomedics has announced that Syncor International will distribute the radiopharmaceutical firm’s CEA-Scan colorectal cancer agent. The deal complements a distribution deal signed earlier this year
Philips signs off on CEOs replacement
Immunomedics has announced that Syncor International will distribute the radiopharmaceutical firms CEA-Scan colorectal cancer agent. The deal complements a distribution deal signed earlier this year with Bergen Brunswig (SCAN Special Report 6/98), which replaced a prior arrangement with Mallinckrodt.
Bergen Brunswig will provide nonradiolabeled CEA-Scan to Syncor, which will radiolabel the CEA-Scan with technetium at its 118 U.S. radiopharmacies, according to an Immunomedics spokesperson. Syncor, of Woodland Hills, CA, will then provide CEA-Scan to its customers in ready-to-use dosages. Syncor will also support Morris Plains, NJ-based Immunomedics with its own sales force.
Study Shows No Impact of Hormone Therapy on PET/CT with 18F-Piflufolastat in PCa Imaging
May 7th 2025For patients with recurrent or metastatic prostate cancer, new research findings showed no significant difference in the sensitivity of 18F-piflufolastat PET/CT between patients on concurrent hormone therapy and those without hormone therapy.
